In Situ Gel Drug Delivery Market Size, Share, & Trends Analysis Report By By Route Of Administration, By Application, By End-user, By Region, And Segment Forecasts, 2022 To 2030

In situ gel, drug delivery devices are polymeric formulations that are administered in the sol form and once it is administered, it undergoes gelatin in situ, in order to form a gel. The formation of the gel is determined by factors such as pH change and temperature modulation. The presence of ultraviolet irradiation and ions, from which the drug is released in a persistent and controlled manner also plays a vital role in determining the formation of the gel.

Over the last decade, the development of in situ gel drug delivery has attained increasing attention within the scientific community. This is due to the advantages it offers, such as; ease of administration, sustained drug release at the administration site, and prolonged residence time, which in turn offers patient compliance and comfort. Moreover, it can also be administered through various routes to achieve a local or systemic effect of the loaded drug.

In situ gel, drug delivery systems have helped to encounter the bioavailability problems that were earlier a major problem while administering drugs using a conventional delivery system, in the treatment of ophthalmic disorders. In addition, the increasing prevalence of ophthalmic diseases is further expected to accelerate the demand and growth of in situ gel drug delivery systems over the forecast period. According to the National Glaucoma Research, in 2020, about 80 million individuals had glaucoma worldwide and this is expected to rise to 111 million by 2040.

                                   Dermatome Device Market Segmentation

Based on application, the ophthalmic segment dominates the market, as currently there are a large number of products available for the treatment of ocular disorders. On the other hand, the oncology segment will experience maximum growth due to increasing investment and research by strong pharmaceutical companies in this field.

Key players operating in the in situ gel drug delivery market include MERCK & CO., Inc., Astra Zeneca, Bausch Health, Macromed, Sun Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Akorn Operating Company LLC and Laboratoires Théa S.A.S.